Adaptive Biotechnologies (NASDAQ:ADPT) and NeoGenomics (NASDAQ:NEO) have announced a multi-year exclusive collaboration aimed at advancing minimal residual disease (MRD) monitoring options for patients with select blood cancers.
The companies stated that, with the growing adoption of MRD testing, the integration of Adaptive’s clonoSEQ—the first and only FDA-approved in vitro diagnostic test to detect MRD in lymphoid cancers—with NeoGenonomics’ COMPASS and CHART, a suite of personalized assessment services for complex blood cancers, will assist oncologists in providing patients with personalized treatment strategies. This integration employs advanced methods for evaluating patient risk and delivers real-time insights into disease progression.
Chad Robins, CEO and co-founder of Adaptive, said, “Our partnership with NeoGenomics reflects our shared commitment to empowering oncologists and pathologists to deliver the highest quality patient care. As a leader in oncology testing with an extensive menu of precision oncology offerings, NeoGenomics is a natural partner for us. We are proud of this collaboration, which expands access to the valuable insights that clonoSEQ MRD results offer, ultimately helping more providers and patients benefit from knowing their MRD status.”
Chris Smith, CEO of NeoGenomics, commented, “MRD testing is widely recognized as an integral part of blood cancer patient care, serving not only as a powerful prognostic tool but also guiding clinical decision-making. NeoGenomics is proud to offer our customers access to clonoSEQ, the gold standard for clinical MRD monitoring. We believe Adaptive is the market leader in heme MRD and this strategic commercial collaboration reflects our broader commitment to providing best-in-class, personalized diagnostic testing for patients for their entire cancer journey while strengthening our leadership position in hematology testing.”
